PhaseBio Pharmaceuticals, Inc.

NASDAQ (USD): PhaseBio Pharmaceuticals, Inc. (PHAS)

Last Price

0.07

Today's Change

0.00 (0.00%)

Day's Change

0.00 - 0.00

Trading Volume

0

Profile
PHAS

Exchange:  NASDAQ Global Market NASDAQ Global Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Jonathan Mow Mr. Jonathan Mow

Full Time Employees:  60 60

IPO Date:  2018-10-18 2018-10-18

CIK:  0001169245 0001169245

ISIN:  US7172241090 US7172241090

CUSIP:  717224109 717224109

Beta:  2.87 2.87

Last Dividend:  0.00 0.00

Dcf Diff:  1.42 1.42

Dcf:  2.42 2.42

Description

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Address

1 Great Valley Pkwy Ste 30,
Malvern, PENNSYLVANIA 19355, US

16109816500

http://phasebio.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment